Serveur d'exploration sur le thulium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[Treatment of benign prostatic hyperplasia with the Revolix laser].

Identifieur interne : 000552 ( PubMed/Corpus ); précédent : 000551; suivant : 000553

[Treatment of benign prostatic hyperplasia with the Revolix laser].

Auteurs : Stefano Mattioli ; Rubén Mu Oz ; Ricard Recasens ; Carlos Berbegal ; Jordi Cortada ; José M. Urmeneta ; Heinrich Teichmann

Source :

RBID : pubmed:19140585

English descriptors

Abstract

The treatment of benign prostatic hyperplasia (BPH) with the Revolix laser is effective. Its versatility enables 2 types of techniques: vaporresection and vaporization. Its chromophore target is water, like the holmium laser, with the difference that it may be used in both a continuous and pulsed mode. The continuous wave enables a precise cut and excellent hemostasis without diffusion to the neighbor tissues (0.2 mm penetration below the cut zone) with an excellent vision of the operative field. We report our experience after three years of treatment.

PubMed: 19140585

Links to Exploration step

pubmed:19140585

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">[Treatment of benign prostatic hyperplasia with the Revolix laser].</title>
<author>
<name sortKey="Mattioli, Stefano" sort="Mattioli, Stefano" uniqKey="Mattioli S" first="Stefano" last="Mattioli">Stefano Mattioli</name>
<affiliation>
<nlm:affiliation>Instituto Clinico San Ambrogio, Milan, Italia.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mu Oz, Ruben" sort="Mu Oz, Ruben" uniqKey="Mu Oz R" first="Rubén" last="Mu Oz">Rubén Mu Oz</name>
</author>
<author>
<name sortKey="Recasens, Ricard" sort="Recasens, Ricard" uniqKey="Recasens R" first="Ricard" last="Recasens">Ricard Recasens</name>
</author>
<author>
<name sortKey="Berbegal, Carlos" sort="Berbegal, Carlos" uniqKey="Berbegal C" first="Carlos" last="Berbegal">Carlos Berbegal</name>
</author>
<author>
<name sortKey="Cortada, Jordi" sort="Cortada, Jordi" uniqKey="Cortada J" first="Jordi" last="Cortada">Jordi Cortada</name>
</author>
<author>
<name sortKey="Urmeneta, Jose M" sort="Urmeneta, Jose M" uniqKey="Urmeneta J" first="José M" last="Urmeneta">José M. Urmeneta</name>
</author>
<author>
<name sortKey="Teichmann, Heinrich" sort="Teichmann, Heinrich" uniqKey="Teichmann H" first="Heinrich" last="Teichmann">Heinrich Teichmann</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:19140585</idno>
<idno type="pmid">19140585</idno>
<idno type="wicri:Area/PubMed/Corpus">000552</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000552</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">[Treatment of benign prostatic hyperplasia with the Revolix laser].</title>
<author>
<name sortKey="Mattioli, Stefano" sort="Mattioli, Stefano" uniqKey="Mattioli S" first="Stefano" last="Mattioli">Stefano Mattioli</name>
<affiliation>
<nlm:affiliation>Instituto Clinico San Ambrogio, Milan, Italia.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mu Oz, Ruben" sort="Mu Oz, Ruben" uniqKey="Mu Oz R" first="Rubén" last="Mu Oz">Rubén Mu Oz</name>
</author>
<author>
<name sortKey="Recasens, Ricard" sort="Recasens, Ricard" uniqKey="Recasens R" first="Ricard" last="Recasens">Ricard Recasens</name>
</author>
<author>
<name sortKey="Berbegal, Carlos" sort="Berbegal, Carlos" uniqKey="Berbegal C" first="Carlos" last="Berbegal">Carlos Berbegal</name>
</author>
<author>
<name sortKey="Cortada, Jordi" sort="Cortada, Jordi" uniqKey="Cortada J" first="Jordi" last="Cortada">Jordi Cortada</name>
</author>
<author>
<name sortKey="Urmeneta, Jose M" sort="Urmeneta, Jose M" uniqKey="Urmeneta J" first="José M" last="Urmeneta">José M. Urmeneta</name>
</author>
<author>
<name sortKey="Teichmann, Heinrich" sort="Teichmann, Heinrich" uniqKey="Teichmann H" first="Heinrich" last="Teichmann">Heinrich Teichmann</name>
</author>
</analytic>
<series>
<title level="j">Archivos españoles de urología</title>
<idno type="ISSN">0004-0614</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Equipment Design</term>
<term>Humans</term>
<term>Laser Therapy (instrumentation)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prostatic Hyperplasia (surgery)</term>
</keywords>
<keywords scheme="MESH" qualifier="instrumentation" xml:lang="en">
<term>Laser Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Prostatic Hyperplasia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Equipment Design</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The treatment of benign prostatic hyperplasia (BPH) with the Revolix laser is effective. Its versatility enables 2 types of techniques: vaporresection and vaporization. Its chromophore target is water, like the holmium laser, with the difference that it may be used in both a continuous and pulsed mode. The continuous wave enables a precise cut and excellent hemostasis without diffusion to the neighbor tissues (0.2 mm penetration below the cut zone) with an excellent vision of the operative field. We report our experience after three years of treatment.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">19140585</PMID>
<DateCreated>
<Year>2009</Year>
<Month>01</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted>
<Year>2009</Year>
<Month>03</Month>
<Day>26</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0004-0614</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>61</Volume>
<Issue>9</Issue>
<PubDate>
<Year>2008</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Archivos españoles de urología</Title>
<ISOAbbreviation>Arch. Esp. Urol.</ISOAbbreviation>
</Journal>
<ArticleTitle>[Treatment of benign prostatic hyperplasia with the Revolix laser].</ArticleTitle>
<Pagination>
<MedlinePgn>1037-43</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The treatment of benign prostatic hyperplasia (BPH) with the Revolix laser is effective. Its versatility enables 2 types of techniques: vaporresection and vaporization. Its chromophore target is water, like the holmium laser, with the difference that it may be used in both a continuous and pulsed mode. The continuous wave enables a precise cut and excellent hemostasis without diffusion to the neighbor tissues (0.2 mm penetration below the cut zone) with an excellent vision of the operative field. We report our experience after three years of treatment.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Revolix (thulium) laser has a wavelength of 2013 nm. 2 types of fibers, which reach a potency of up to 70 watts, are used to treat BPH. One frontal fiber for vaporresection and one fiber with side laser emission for vaporization. Both fibers may be combined to treat prostatic hypertrophy. Since the end of 2004 to March 2008 200 patients with BPH were treated. Prostate sizes varied from 20 to 120 g (mean 45 g). 99 patients underwent prostate vaporization, with sizes below 35 g, and 101 patients underwent vaporresection, with prostates over 35 g. Mean hospital time was 24 hours (range 1-4 hours). Mean catheterization time after laser treatment was 16 hours (range 12-72 hours). The efficacy of the treatment was evaluated with uroflowmetry, post void residual and evaluation of the symptoms with the IPSS questionnaire.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The clinical results obtained after Revolix laser are comparable to those obtained after transurethral resection of the prostate, KTP laser vaporization or holmium laser enucleation. We demonstrate on important improvement of symptoms, with a decrease over 50% in the IPSS score, a significant improvement in the uroflowmetry, and a marked decrease of post void residual. No blood transfusions were required. There were only 4 patients that presented post operative acute urinary retention, requiring catheterization for a few days; all of them achieved spontaneous voiding posteriorly. No patient presented urinary incontinence after treatment with the Revolix laser.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In our experience, the Revolix laser has demonstrated being safe, easy to install, with low operative cost, and a very short learning curve. Its efficacy may be better demonstrated using vapor resection for big prostates and vaporization for smaller prostates (the smaller than 35 g). The reduction of prostatic tissue is intermediate with a slight post operative discomfort and a low complication rate.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mattioli</LastName>
<ForeName>Stefano</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Instituto Clinico San Ambrogio, Milan, Italia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Muñoz</LastName>
<ForeName>Rubén</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Recasens</LastName>
<ForeName>Ricard</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berbegal</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cortada</LastName>
<ForeName>Jordi</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Urmeneta</LastName>
<ForeName>José M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Teichmann</LastName>
<ForeName>Heinrich</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>spa</Language>
<PublicationTypeList>
<PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Tratamiento de la hipertrofia benigna de próstata con el láser Revolix.</VernacularTitle>
</Article>
<MedlineJournalInfo>
<Country>Spain</Country>
<MedlineTA>Arch Esp Urol</MedlineTA>
<NlmUniqueID>0064757</NlmUniqueID>
<ISSNLinking>0004-0614</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004867">Equipment Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053685">Laser Therapy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2009</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2009</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2009</Year>
<Month>3</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">19140585</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000552 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000552 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    ThuliumV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:19140585
   |texte=   [Treatment of benign prostatic hyperplasia with the Revolix laser].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:19140585" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ThuliumV1 

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu May 12 08:27:09 2016. Site generation: Thu Mar 7 22:33:44 2024